Impact of molecular residual disease post allografting in myelofibrosis patients

C Wolschke, A Badbaran, T Zabelina… - Bone Marrow …, 2017 - nature.com
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent
allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F …
被引用次数：46 相关文章

Impact of molecular residual disease post allografting in myelofibrosis patients

C Wolschke, A Badbaran, T Zabelina… - Bone marrow …, 2017 - pubmed.ncbi.nlm.nih.gov
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent
allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F …

Impact of molecular residual disease post allografting in myelofibrosis patients

C Wolschke, A Badbaran, T Zabelina… - Bone Marrow …, 2017 - go.gale.com
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent
allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F …

[引用][C] Impact of molecular residual disease post allografting in myelofibrosis patients

C Wolschke, A Badbaran, T Zabelina… - Bone Marrow …, 2017 - cir.nii.ac.jp
Impact of molecular residual disease post allografting in myelofibrosis patients | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

[引用][C] Impact of molecular residual disease post allografting in myelofibrosis patients

C Wolschke, A Badbaran, T Zabelina… - 2017 - publications.goettingen-research …

Impact of molecular residual disease post allografting in myelofibrosis patients.

C Wolschke, A Badbaran, T Zabelina… - Bone Marrow …, 2017 - europepmc.org
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent
allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F …
[PDF] academia.edu

[PDF][PDF] Impact of molecular residual disease post allografting in myelofibrosis patients

Bone Marrow Transplantation, 2017 - academia.edu
Allogeneic stem cell transplantation can cure a substantial number of patients with
myelofibrosis. Relapse is the major case of treatment failure, and depending on disease …